US Department of Health and Human Services

Derived from Strategic Transactions , Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharma

French vaccines company Valneva SE is planning to list on the NASDAQ to fund Phase III studies of the much-needed vaccine for Lyme disease. The company had a dual listing on the Vienna Stock Exchang

Derived from Strategic Transactions , Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biophar

Biopharma’s inherent shortage of new product leads means that finding a good external research partner has become a strategic imperative. It’s a task made harder by the fact that the dance card of the